Testing, Inspection and Certification M&A Multiples 2026: What Buyers Pay and Who Is Buying

By Christoph Totter, Managing Partner, CT Acquisitions. Last verified August 2026. Quarterly refresh target.

Two structural facts make testing, inspection and certification different from almost any trade a buyer will underwrite. First, the spend is mission-critical but tiny: TIC services typically cost less than 1% of a customer’s total project cost yet are legally required, which produces durable, low-cyclicality cash flow that does not get cut when budgets tighten (per Moody’s, 10 July 2024). Second, the market is highly fragmented: the top ten TIC players together control less than a quarter of global revenue despite roughly $44bn to $50bn in combined turnover (Aventis Advisors top-ten data, updated 11 May 2026). Mission-critical recurring demand plus a fragmented base is exactly the combination that sustains both premium public multiples and an active roll-up.

We are CT Acquisitions, a buy-side M&A advisor. This guide covers the industrial TIC industry, the SGS, Bureau Veritas, Intertek and Applus world of materials testing, non-destructive testing, product and electrical safety certification, industrial and energy inspection, commercial environmental and food labs, and management-systems certification. It lays out what buyers appear to pay across tiers, who the active acquirers actually are, and the honest case against the thesis. For clinical and diagnostic laboratories specifically, which serve a different buyer set entirely, see our clinical laboratory guide. Residential property inspection is a different market again; see our home inspection guide.

Why TIC commands premium multiples

The forcing function is regulation, not preference. A manufacturer does not choose to certify a product to a safety standard the way it chooses a marketing agency; it certifies because a regulator, a retailer, or an insurer requires it before the product can be sold, shipped, or installed. That makes the revenue non-discretionary and recurring, because the certification, inspection, or test has to be repeated as products change, standards update, and assets age. Moody’s frames the demand as mission-critical and regulatory-driven, sitting at less than 1% of a customer’s project cost while gating the whole project (Moody’s, 10 July 2024).

The demand base is large and still shifting toward pure-play providers. The global TIC market runs roughly $300 billion a year, with about 40% to 50% of that outsourced to independent providers and the balance still done in-house, growing at roughly 4% a year over 2024 to 2028 (Moody’s, 10 July 2024, a primary credit document and the most citable anchor figure). Vendor estimates vary widely by definition: Bureau Veritas frames the market at EUR 200bn and up, Custom Market Insights put it at $265.6bn for 2025, and other houses cluster growth at 3.4% to 6.3% (vendor estimates, treat as such; the Moody’s $300bn is the anchor). The direction that matters for a seller is the outsourcing tailwind: with roughly half the work still captive inside customers, there is structural room for independent providers to keep taking share, which underwrites the growth story that buyers pay for.

What buyers pay

Before any figure, the tier discipline. Public-company and platform-scale comparables are not what a lower middle market operator trades at, and we label the tier on every one. The published TIC medians describe listed multinationals and large private platforms, not a regional lab.

At the top of the market, the public TIC sector traded at a median EV/EBITDA of roughly 14.3x in November 2025, against a ten-year average of 14.2x, a 2017 peak of 17.2x, and an early-2020 COVID trough of 12.6x (Aventis Advisors TIC valuations report, 21 November 2025). These are public-tier multiples for multi-billion-dollar listed operators. The individual majors sat below that median in summer 2025: SGS at roughly 13.0x LTM, Bureau Veritas at roughly 11.7x, and Intertek at roughly 11.2x (Aventis Advisors and Houlihan Lokey TICC, Summer 2025). A pair of premium names, UL Solutions and ALS, have traded well above the majors, around 18x on a directional basis rather than as a point-in-time quote (directional characterization).

Two things move a TIC multiple inside those bands more than anything else, and growth beats margin. Aventis finds that each roughly 10% of expected two-year revenue growth adds about 1.5x to the EBITDA multiple, and by a second Aventis measure up to about 2.9x (Aventis Advisors, 21 November 2025). Growth expectations move TIC multiples more than margin does, which is why the premium names are the fast-growing ones rather than simply the most profitable ones.

Below roughly $1M of owner earnings, small lab, inspection and NDT businesses are typically priced on seller’s discretionary earnings (SDE) rather than EBITDA, because the owner’s labor and add-backs dominate the economics. As earnings scale above roughly $1M, the convention shifts to EBITDA. The TIC operator range skews larger than most trades, because the citable deals are platform and public, so the SDE-priced tuck-ins are the smaller feed into those platforms rather than the headline transactions. We never quote a multiple on revenue; TIC valuation is EV/EBITDA, and where an enterprise value appears it is a disclosed EV, not a revenue multiple. And we talk in turns rather than dollars for valuation impact, because a turn of EBITDA is what actually moves between a 7x lab and a 14x platform.

The sub-segments and how each consolidates

TIC is not one market but a set of sub-segments with different economics. By spend, consumer goods and retail runs about EUR 23bn, roughly 12% of the market; food and agriculture is another EUR 23bn, roughly 12%; oil and gas is about EUR 20bn, roughly 10%; and the balance spreads across construction and infrastructure, industrial and energy inspection, life sciences, marine, and automotive (Aventis Advisors TIC industry page, 10 July 2025; Bureau Veritas framing). The hottest areas for consolidation and premium pricing are food safety and traceability, EV-battery validation, and ESG and sustainability certification.

How a sub-segment consolidates depends on its business model, not on any claim that one segment trades at a structurally higher multiple than another. Life sciences, pharma and environmental testing is the archetypal laboratory roll-up: capital-intensive buy-and-build of physical labs, with Eurofins as the model and Normec following the same playbook. Certification and inspection work, meaning product safety, electrical safety, and management-systems certification, is more asset-light and recurring, so it consolidates through capability and accreditation rather than through heavy lab capex. The contrast that matters to a buyer is capital intensity and business model, not a multiple ranking; the premium in TIC attaches to growth, with UL and ALS as the premium names, not to certification versus labs as a category.

Who is buying

The buyer universe splits three ways: listed strategics that acquire constantly, private equity platforms building toward an exit, and nonprofit or foundation-owned majors that structurally do not sell. Knowing which is across the table shapes everything about a process.

The listed strategics are the most active acquirers in the industry. SGS (SIX: SGSN), the largest TIC company at roughly $8.76bn revenue, has completed 97 acquisitions since 2014; Bureau Veritas (Euronext Paris: BVI, roughly $7.85bn revenue) has done 61 over a comparable span. Intertek (LSE: ITRK) reported roughly $4.6bn LTM revenue as of September 2025. Eurofins (Euronext Paris: ERF, EUR 6.95bn in 2024) remains Martin-family-controlled, with 32.7% of shares and 66.2% of voting rights as of 30 June 2024, and is the model for capital-intensive lab roll-up. UL Solutions (NYSE: ULS, roughly $3.1bn revenue) completed its IPO in April 2024. These are the buyers most likely to take a strong regional platform to full scale.

The private equity platforms are the other active pole, each date-stamped by owner. Applus+ was taken private in 2024 by TDR Capital and I Squared Capital. Element Materials has been owned by Temasek since 2022. SOCOTEC is held by Cobepa and CD&R, with Bpifrance and Mubadala taking a minority in 2024. Normec has been backed by Astorg since 2020 and moved into a EUR 1.4bn continuation fund in July 2024. Cotecna sits outside both camps, majority-owned by Frank Piedelievre alongside the Massey family. These sponsors are buyers, and their platforms are the ones actively acquiring lab and inspection tuck-ins.

The nonprofit and foundation-owned majors are a structurally different animal, because they largely cannot be bought. DEKRA, owned by DEKRA e.V. and describing itself as the world’s largest non-listed inspection body, ran EUR 4.29bn in 2024. TUV SUD (TUV SUD e.V. and Foundation, roughly $4.0bn), TUV Rheinland (e.V.), TUV NORD (an e.V. chain), and DNV (the Stiftelsen Det Norske Veritas foundation) are all association or foundation-owned, not private equity. Kiwa sits under SHV Holdings and the Fentener van Vlissingen family. For a seller, these names are strong strategic partners and competitors but rarely exit candidates, which quietly narrows the buyer pool in some sub-segments. For the broader sponsor map by sector, see our private equity platforms by sector guide.

The two flagship recent events

The Applus+ take-private is the flagship recent TIC deal, and it is instructive for exactly what it did and did not print. TDR Capital and I Squared Capital, acting through the vehicle Amber EquityCo, won the company at EUR 12.78 per share, implying an enterprise value of roughly EUR 2.5 billion (Moody’s, 10 July 2024). Apollo bid first, moving from EUR 9.50 to EUR 10.65, lost the bidding war, and withdrew in May 2024. Against FY2023 revenue of EUR 2,058m and Moody’s-adjusted EBITDA of EUR 320m (proforma EUR 346m), the deal works out to an implied roughly 7.8x FY23 EBITDA, or about 7.2x on the proforma figure. That 7.8x is a derived figure: it comes from the disclosed roughly EUR 2.5bn EV against FY2023 EBITDA of EUR 320m (Moody’s, July 2024), and Moody’s did not print a headline multiple. Proforma net debt to EBITDA came to 5.9x. The shares were suspended on 26 April 2024 and Applus+ was delisted effective 27 November 2024, not June.

The UL Solutions IPO is the other marker. UL Solutions priced on 11 April 2024 at $28.00 per Class A share and first traded on the NYSE on 12 April 2024 under the ticker ULS (ul.com pricing release; SEC 424B4). Every share sold was secondary, offered by the nonprofit UL Standards & Engagement (ULSE), which retains majority voting control; UL Solutions itself received no primary proceeds. The offering was upsized from 33.8m shares at filing to 38,870,000 final shares, roughly $1.08bn gross using the 38.87m count. It is a clean example of a nonprofit parent monetizing part of a TIC operator without ceding control.

What separates operators inside a band

Two TIC businesses with identical EBITDA can price a couple of turns apart, and the variables buyers appear to reward are specific. Accreditation scope is first: ISO 17025 for testing and calibration labs and ISO 17020 for inspection bodies are the credentials that let a business do regulated work at all, so scope is a real barrier rather than a nicety. Then the share of recurring and contracted revenue, because a book anchored in repeat, mandated testing prices better than one built on one-off project work. The mix of regulatory-mandated versus discretionary work matters for the same reason the whole thesis does: mandated demand is stickier. Growth trajectory is the single biggest multiple mover, per the Aventis growth finding above. Sub-segment positioning counts, since food safety, EV-battery and ESG work sit where consolidation is hottest. And customer concentration and asset intensity round it out: a diversified book prices better than a concentrated one, and an asset-light certification model carries different economics than a capital-heavy lab. Buyers appear to pay up for operators that combine broad accreditation, high contracted-revenue share, and a credible growth path.

The honest case against

We would rather an owner hear the counter-thesis from us than discover it in diligence. The premium TIC story has real limits.

The premium multiples are for scaled growth platforms, not small labs. The 14x public median and the 18x premium names describe large, fast-growing, listed operators. The reality for a small regional lab is closer to 7x, roughly half the listed median (Aventis Advisors, 21 November 2025). Carrying a headline multiple into a small-company conversation sets an expectation the market will not meet.

Public TIC multiples have de-rated. The sector sat at a 17.2x peak in 2017 and traded at roughly 14.3x in November 2025 (Aventis Advisors, 21 November 2025). The direction of travel over that span is down, not up, and a seller underwriting today’s multiple should not assume the 2017 peak returns.

Private lower middle market labs carry real discounts. A privately held lab or inspection business is illiquid and carries a private-company discount on top of its smaller size (Aventis Advisors, 21 November 2025). That discount is not a negotiating tactic; it is how the market prices the difference between a listed multinational and a single owner-operated shop.

Even the EUR 2.5bn Applus platform printed only about 7.8x. The flagship take-private of a EUR 2.5bn enterprise-value TIC platform worked out to an implied roughly 7.8x FY23 EBITDA, derived from the disclosed EV and Moody’s EBITDA (Moody’s, July 2024), not a 14x. If a EUR 2.5bn platform changed hands near 8x, public-comp medians clearly overstate what most sellers actually get. Mandated demand is durable, but the growth that drives the multiple is not guaranteed, and the nonprofit ownership of several majors limits exit routes and thins the strategic-buyer pool in some sub-segments.

Where lower middle market tuck-ins fit

The buy-side angle follows directly from the two opening facts. Because the top ten players hold less than a quarter of global revenue (Aventis Advisors, 11 May 2026), the base of small labs, inspection bodies and NDT shops is enormous and fragmented, and the private equity platforms named above are actively acquiring into it. Sub-$1M-earnings shops are SDE-priced and feed the platform roll-ups; they are the raw material of the buy-and-build, not the headline deals. For an owner of a smaller lab or inspection business, that fragmentation is the opportunity: there is a real, active buyer set for a well-accredited, recurring-revenue tuck-in, even though the operator will price on SDE well below the platform medians. For an adjacent regulated services buyer map, see our security guard M&A multiples guide.

Preparing over 18 to 36 months

Owners who want a platform-tier outcome rather than a tuck-in-tier one tend to spend the run-up doing a few concrete things. Broaden and document accreditation scope, since ISO 17025 and ISO 17020 credentials are the barrier a buyer verifies first. Shift the revenue mix toward contracted and recurring, mandated testing and away from one-off projects, because contracted-revenue share is a direct multiple input. Position deliberately inside a sub-segment where consolidation is active, food safety, EV-battery validation, or ESG certification, rather than staying a generalist. Build a demonstrable growth trajectory, since growth moves the TIC multiple more than margin does. Reduce customer concentration so no single account can reset the economics. And clean up the financials so add-backs are defensible and the SDE-to-EBITDA story is clear at the earnings level the business will actually be sold at. None of this is fast, which is why the honest window is measured in years.

About CT Acquisitions

We are CT Acquisitions, a buy-side M&A advisor working across the testing, inspection and certification and adjacent regulated-services trades. Our network includes 100+ capital partners, and our work is orienting owners and buyers to what the market is actually doing rather than what a headline multiple suggests.

Frequently asked questions

What EV/EBITDA multiple do TIC businesses sell for?
It depends entirely on tier. The listed public TIC sector traded at a median of roughly 14.3x in November 2025, with individual majors around 11x to 13x and premium names like UL Solutions and ALS around 18x on a directional basis (Aventis Advisors). Small regional labs have tended to transact at roughly half the listed median, around 7x, plus a private-company discount. Those public figures are not what a lower middle market operator should expect.

When does a TIC business get priced on SDE versus EBITDA?
Below roughly $1M of owner earnings, small lab, inspection and NDT businesses are generally priced on seller’s discretionary earnings (SDE). Above roughly $1M, the convention shifts to EBITDA. The TIC operator range skews larger than most trades because the citable deals are platform and public, so the SDE-priced shops are the tuck-in feed into platforms rather than the headline transactions.

What multiple did the Applus+ take-private print?
An implied roughly 7.8x FY2023 EBITDA, which is a derived figure. It comes from the disclosed enterprise value of about EUR 2.5 billion against FY2023 Moody’s-adjusted EBITDA of EUR 320m (Moody’s, July 2024); Moody’s did not print a headline multiple. On the proforma EUR 346m EBITDA it works out to about 7.2x. TDR Capital and I Squared Capital were the acquirers; Apollo bid first and withdrew in May 2024.

When was Applus+ delisted?
The shares were suspended on 26 April 2024 and Applus+ was delisted effective 27 November 2024. It was taken private by TDR Capital and I Squared Capital at EUR 12.78 per share.

What were the terms of the UL Solutions IPO?
UL Solutions priced on 11 April 2024 at $28.00 per Class A share and first traded on the NYSE under ULS on 12 April 2024. All shares were secondary, sold by the nonprofit UL Standards & Engagement, which retains majority voting control, so UL Solutions received no primary proceeds. The offering was upsized to 38,870,000 final shares, roughly $1.08bn gross (ul.com; SEC 424B4).

Why does TIC command premium multiples at all?
Because the revenue is mission-critical, regulation-mandated, and recurring while costing less than 1% of a customer’s total project cost, which produces durable, low-cyclicality cash flow (Moody’s, July 2024). The market is also highly fragmented, with the top ten players holding less than a quarter of global revenue, which sustains both premium public multiples and an active roll-up (Aventis Advisors).

Which TIC majors are not realistic sellers?
Several majors are nonprofit, association, or foundation-owned rather than private equity-backed, which structurally limits their exit routes. DEKRA is owned by DEKRA e.V., TUV SUD by TUV SUD e.V. and a Foundation, TUV Rheinland and TUV NORD are e.V. entities, and DNV sits under the Stiftelsen Det Norske Veritas foundation. These are strong strategic players but rarely exit candidates.

How should an owner prepare a TIC business for sale?
Over 18 to 36 months, broaden and document accreditation scope (ISO 17025 for labs, ISO 17020 for inspection), shift the revenue mix toward contracted and mandated recurring work, position inside an active consolidation sub-segment such as food safety, EV-battery validation, or ESG certification, build a demonstrable growth trajectory since growth moves the multiple more than margin, reduce customer concentration, and clean up the financials so the SDE-to-EBITDA story is defensible at the earnings level the business will be sold at.

Disclaimer

CT Strategic Partners LLC dba CT Acquisitions is a buy-side M&A advisor. We are not a registered investment bank, broker-dealer, or appraiser. Multiple ranges are directional observations from cited sources and active engagement observations, not point estimates, appraisals, or descriptions of specific undisclosed transactions. Platform-scale and public-company figures are not comparable to lower middle market operators. Ownership and sponsor attributions are verified as of the stated date, not permanently. Individual outcomes vary materially. Past patterns are not a guarantee of future results.